Skip to main content
SpringerLink
Log in

Second-Line Chemotherapy for Non-Small-Cell Lung Cancer

  • Chapter
Tumors of the Chest

  • 809 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1997; 47:5.

    PubMed  CAS  Google Scholar 

  2. Ginsberg JK, Kris MG, Armstrong JG. Cancer of the lung: non-small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds.) Cancer: Principles and Practice of Oncology, 4th edn. Lippincott, Philadelphia, 1993; p 673.

    Google Scholar 

  3. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123:226S.

    Article  PubMed  Google Scholar 

  4. Johnson DH. Locally advanced, unresectable non-small cell lung cancer: new treatment strategies. Chest 2000;117(2):123S.

    Article  PubMed  CAS  Google Scholar 

  5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899.

    Google Scholar 

  6. Buccheri G, Vola F, Ferrigno D. Aspects of quality of life in patients with lung cancer: a three observer evaluation study. Int J Oncol 1993; 2:537.

    Google Scholar 

  7. Slevin ML, Stubbs L, Plant HJ. Attitudes to chemotherapy: comparing views of patients with cancer and those of doctors, nurses, and general public. Br Med J 1990;300:1458.

    Article  CAS  Google Scholar 

  8. Faller H, Lang H, Schilling S, et al. Emotional distress and hope in lung cancer patients as perceived by patients, relatives, physicians and interviewers. Psychol Oncol 1995; 4:21.

    Google Scholar 

  9. Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin in advanced non-small cell lung cancer: re sults of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360.

    PubMed  Google Scholar 

  10. Sandier AT, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin VS cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18:122.

    Google Scholar 

  11. Shepherd FA, Dancey J, Ramalau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095.

    PubMed  CAS  Google Scholar 

  12. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43:183.

    Article  PubMed  Google Scholar 

  13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens. J Clin Oncol 2000; 18:2354.

    PubMed  CAS  Google Scholar 

  14. Gridelli C, Gallo C, Di Maio M, et al. A randomized clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91(12):1996.

    Article  PubMed  CAS  Google Scholar 

  15. Gervais R, Ducolone A, Breton JL, et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16(l):90.

    Article  PubMed  CAS  Google Scholar 

  16. Camps C, Massuti B, Jimenez AM, et al. Second-line docetaxel administered every 3 weeks versus weekly in advanced NSCLC: a Spanish Lung Cancer Group (SLCG) phase III trial. Proc Am Soc Clin Oncol 2003; 22:625.

    Google Scholar 

  17. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002; 20(5):1344.

    Article  PubMed  Google Scholar 

  18. Shih C, Chen VJ, Gossett LS, et al. LY 231514, a pyrolo (2,3-d) pyromidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997; 57:1116.

    PubMed  CAS  Google Scholar 

  19. Hammond L, Baker SD, Villalona-Calero SG, et al. A phase I and pharmacokinetic study of the multitargeted antifol (MTA) LY 231514 with folic acid (abstract). Ann Oncol 1998; 9:620.

    Google Scholar 

  20. Niyikiza C, Baker SD, Switz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1:545.

    PubMed  CAS  Google Scholar 

  21. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.

    Article  PubMed  CAS  Google Scholar 

  22. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.

    Article  PubMed  CAS  Google Scholar 

  23. Pronzato P, Landucci M, Vaira F. Failure of vinorelbine to produce responses in pre-treated non-small-cell lung cancer. Anticancer Res 1994; 14:1413.

    PubMed  CAS  Google Scholar 

  24. Rinaldi M, Delia Giulia M, Venturo I. Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1994; 13:360A.

    Google Scholar 

  25. Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small-cell lung cancer. Lung Cancer 1994; 11(130):1.

    Google Scholar 

  26. Depierre A, Freyer G, Jassem J, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001; 12(12):1677.

    Article  PubMed  CAS  Google Scholar 

  27. De Pas T, De Braud F, Mandala M, et al. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 2001; 31(2–3):267.

    Article  PubMed  Google Scholar 

  28. Chen YM, Lee CS, Lin WC, et al. Phase II study with vinorelbine and cisplatin in advanced non-small-cell lung cancer after failure of previous chemotherapy. J Chin Med Assoc 2003; 66(4):241.

    PubMed  Google Scholar 

  29. Agelaki S, Bania H, Kouroussis C, et al. Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small-cell lung cancer. A multicenter phase II study. Lung Cancer 2001; 34(4):S77.

    Article  PubMed  Google Scholar 

  30. Seo-Young S, Won SK, Kihyun K, et al. Vinorelbine, Ifosfamide, and Cisplatin combination in advanced non-small-cell lung cancer. Jpn J Clin Oncol 2003; 33(10):509.

    Article  Google Scholar 

  31. Rosvold E, Langer CJ, Scholder R, et al. Salvage therapy with gemcitabine in advanced non-small-cell lung cancer progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 1998; 17:463a

    Google Scholar 

  32. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999; 17:2081.

    PubMed  CAS  Google Scholar 

  33. Rossi A, Perrone F, Barletta E, et al. Activity of gemcitabine in cisplatin pretreated patients with non-small-cell lung cancer: a phase II trial. Proc Am Soc Clin Oncol 1999; 18:484a.

    Google Scholar 

  34. Reddy GR, Gandara DR, Edelman MJ, et al. Gemcitabine in platinum treated non-small-cell lung cancer. Proc Am Soc Clin Oncol 1999; 18:521a.

    Google Scholar 

  35. Garfield DH, Dakhil SR, Whittaker TL, et al. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1998; 17:484a.

    Google Scholar 

  36. Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 2000; 27(1):47.

    Article  PubMed  CAS  Google Scholar 

  37. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non small cell lung carcinoma patients: a Minnie Pearl cancer research network phase II trial. Cancer 2000; 88(6):1353.

    Article  PubMed  CAS  Google Scholar 

  38. Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 2001; 37(8):972.

    Article  PubMed  CAS  Google Scholar 

  39. Pectasides D, Kalofonos HP, Samantas E, et al. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-operative Oncology Group. Anticancer Res 2001; 21(4B):3005.

    PubMed  CAS  Google Scholar 

  40. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced non small cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 2002; 95(2):340.

    Article  PubMed  CAS  Google Scholar 

  41. Chen YM, Perng RP, Lee CS, et al. Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol 2003; 26(6):567.

    Article  PubMed  CAS  Google Scholar 

  42. Park YH, Lee JC, Kim CH, et al. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Oncol 2004; 34(5):245.

    Article  Google Scholar 

  43. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, An camptothecin derivative, in patients with primary lung cancer. CPT-11 co-operative group. Jpn J Cancer Chemother 1991; 18:1013.

    CAS  Google Scholar 

  44. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991; 18:607.

    CAS  Google Scholar 

  45. Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999; 22:399.

    Article  PubMed  CAS  Google Scholar 

  46. Watchers FM, Groen HJ, Biesma B, et al. A randomized phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small cell lung cancer who failed first-line treatment. Br J Cancer 2005; 92(1):15.

    Article  CAS  Google Scholar 

  47. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005; 16(2):294.

    Article  PubMed  CAS  Google Scholar 

  48. Font A, Sanchez JM, Taron M, et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuornosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003; 21(4):435.

    Article  PubMed  CAS  Google Scholar 

  49. Gonzalez Cao M, Aramendia JM, Salgado E, et al. Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small cell lung cancer: a phase II study. Am J Clin Oncol 2002; 25(5):480.

    Article  PubMed  Google Scholar 

  50. Kakolyris S, Kourousis C, Souglakos J, et al. Cisplatin and irinotecan (CPT-11) as second-line treatment with advanced non-small cell lung cancer. Lung Cancer 2001; 34(4):S71.

    Article  PubMed  Google Scholar 

  51. Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999; 22(4):399.

    Article  PubMed  CAS  Google Scholar 

  52. Han JY, Lee DH, Kim HY, et al. A phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003; 9(16):5909.

    PubMed  CAS  Google Scholar 

  53. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomized, phase II study. Br J Cancer. 2004; 9:482.

    Article  CAS  Google Scholar 

  54. Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:347.

    PubMed  Google Scholar 

  55. Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14:503.

    PubMed  CAS  Google Scholar 

  56. Weitz JJ, Marschke RF Jr, Sloan JA, et al. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small-cell lung cancer. Lung Cancer 2000; 28:157.

    Article  PubMed  CAS  Google Scholar 

  57. Rinaldi DA, Lormand NA, Brierre JE, et al. A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced non small cell lung carcinoma. Cancer 2002; 95(6):1274.

    Article  PubMed  CAS  Google Scholar 

  58. Tan V, Herrera C, Einzig AJ, et al. Taxol is active as a 3-or 24-h infusion in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14:366A.

    Google Scholar 

  59. Murphy WK, Winn RJ, Huber M, et al. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy. Proc Am Soc Clin Oncol 1994; 13:363A.

    Google Scholar 

  60. Ruckdeschel J, Wagner H, Williams C, et al. Second-line therapy for resistant metastatic non-small cell lung cancer: the role of Taxol. Proc Am Soc Clin Oncol 1994; 13:357A.

    Google Scholar 

  61. Hainsworth JD, Thompson DS, Greco FA, et al. Paclitaxel by 1-h infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13:1609

    PubMed  CAS  Google Scholar 

  62. Nauman C, DeLaney TF, Park J, et al. Paclitaxel (Taxol) as a single agent salvage therapy in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16:476A.

    Google Scholar 

  63. Socinski MA, Steagal A, Gillenwater H, et al. Second-line chemotherapy with 96-h infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II study. Cancer Invest 1999; 17:181.

    Article  PubMed  CAS  Google Scholar 

  64. Chang AY, Boros L, Garrow A, et al. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 1995; 22(6):124.

    PubMed  CAS  Google Scholar 

  65. Juan O, Albert A, Ordono F, et al. Low-dose paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn J Clin Oncol 2002; 32(11):449.

    Article  PubMed  Google Scholar 

  66. Socinski MA, Schell MJ, Bakri K, et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV non-small cell lung carcinoma who failed first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002; 95(6):1265.

    Article  PubMed  CAS  Google Scholar 

  67. Sculier JP, Berghmans T, Lafitte JJ, et al. A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer 2002; 37(1):73.

    Article  PubMed  CAS  Google Scholar 

  68. Buccheri G, Ferrigno D, Cuneo Lung Cancer Study Group. Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 2004; 45(2):227.

    Article  PubMed  Google Scholar 

  69. Ceresoli GL, Gregore V, Cordio S, et al. Phase II of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 44(2):231.

    Article  PubMed  Google Scholar 

  70. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66(5):347.

    Article  PubMed  CAS  Google Scholar 

  71. Esteban E, Gonzalez de Sande L, Fernandez Y, et al. Prospective randomized phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003; 14(11):1640.

    Article  PubMed  CAS  Google Scholar 

  72. Clinical trial phase I–II: Oral taxane in combination with Pemetrexed (Alimta) in patients with recurrent non-small cell lung cancer. www.cancer.gov.

    Google Scholar 

  73. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD 1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL-2). Proc Am Soc Clin Oncol 2002; 21:292a.

    Google Scholar 

  74. Giaccone G, Johnson D, Scagliotti GV, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib (ZD 1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). Proc Am Soc Clin Oncol 2003; 22:627a.

    Google Scholar 

  75. West HL, Franklin WA, Gurnerlock P, et al. ZD1839 (Iressa) in advanced bronchioalveolar carcinoma (BAC): a preliminary report of SWOG S0126. 10th World Conference on Lung Cancer, Vancouver, Canada, Lung Cancer 2003; 30; 81A.

    Google Scholar 

  76. Clinical trial phase III. Oral ZD1839 (Iressa) versus intravenous Docetaxel in patients with non-small cell lung cancer. www.cancer.gov.

    Google Scholar 

  77. Erlotinib (Tarceva) extends survival in advanced lung cancer. ASCO annual meeting, New rleans, June 5, 2004. www.cancer.gov.

    Google Scholar 

  78. Docetaxel or Pemetrexed with or without Cetuximab in patients with recurrent or progressive non-small cell lung cancer. www.cancer.gov.

    Google Scholar 

  79. American Society of Clinical Oncology Treatment Guidelines for Unresectable NSCLC. J Clin Oncol 1997; 15:2996.

    Google Scholar 

  80. American Society of Clinical Oncology. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1998; 15(8):2996.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Department of Medicine Athens Medical School, Sotria General Hospital, Athens, Greece

    Eleni Karapanagiotou

  2. Oncology Unit Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos

Authors
  1. Eleni Karapanagiotou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos N. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Karapanagiotou, E., Syrigos, K.N. (2006). Second-Line Chemotherapy for Non-Small-Cell Lung Cancer. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_24

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation